Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Dana-Farber Cancer Institute
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Lymphoma Research Foundation
Information provided by (Responsible Party):
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: February 9, 2010
Last updated: October 25, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2019
  Estimated Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)